Skip to main content

Table 2 Comparison of primary and secondary outcomes

From: The effect of dobutamine in sepsis: a propensity score matched analysis

Outcomes n (%) Original patients (before matching) PSM adjusted patients (after matching)
Non-dobutamine group (N = 2165) Dobutamine group (N = 121) OR (95%CI) P value Non-dobutamine group (N = 334) Dobutamine group (N = 118) OR (95% CI) P value
Hospital mortality 754 (34.8%) 72 (59.5%) 2.75 (1.89–4.00) 0.000 165 (49.4%) 71 (60.2%) 1.55 (1.01–2.37) 0.044
MV use 1312 (60.6%) 108 (89.3%) 5.40 (3.02–9.66) 0.000 268 (80.2%) 105 (89.0%) 1.99 (1.05–3.76) 0.032
RRT use 208 (9.6%) 28 (23.1%) 2.83 (1.81–4.43) 0.000 56 (16.8%) 27 (22.9%) 1.47 (0.88–2.47) 0.140
Norepinephrine free days 13.01 ± 13.74 11.47 ± 11.10 Na 0.255 12.68 ± 13.54 11.34. ± 11.20 Na 0.360
Cardiac arrhythmias 912 (42.1%) 68 (56.2%) 1.76 (1.22–2.55) 0.002 171 (51.2%) 67(56.8%) 1.25 (0.82–1.91) 0.297
Duration of ICU stay (days) 8.08 ± 9.97 11.77 ± 11.09 Na 0.000 10.20 ± 10.43 11.70 ± 11.18 Na 0.189
Duration of hospital stay (days) 14.98 ± 15.15 14.98 ± 12.22 Na 0.997 15.54 ± 14.22 14.79 ± 12.29 Na 0.611
  1. MV mechanical ventilation, RRT renal replacement therapy